News

The injection is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. Adenosine features the company’s PreventIV Measures packaging and labeling, designed

Additionally, Eisai has assigned the patent right for its metabolic enzyme inhibitor E7727 to Otsuka. As part of the deal, Eisai will transfer to Otsuka its rights to

The announcement means a streamlining of the complex process of clinical research studies, making the setting up of such studies faster and easier by reducing bureaucracy and duplication.

This collaboration will enable Lundbeck’s researchers to take decisive steps towards new and better treatment of the debilitating and life-long brain disease that is schizophrenia. This joint project

Distinguished by a novel chimeric gene segment design, the Trianni platform provides Takeda with easy access to a complete human antibody repertoire that has been optimized for the

The 808 patent expires on 01 September 2015 and claims a process for manufacturing the active ingredient of the company’s relapsing-remitting multiple sclerosis (RRMS) product, Copaxone (glatiramer acetate

Hugel is the leading producer of anti-aging and Botulinum Toxin products in South Korea and Asia. Croma-Pharma managing director and owner Andreas Prinz noted that the company is

The application of Novozymes’ VELTIS technology in the drug delivers an extended half-life which will enable patients to inject only once per week. Novozymes business development executive vice

In the unanimous 14 – 0 decision, the AIDAC found that substantial evidence of the safety and effectiveness of SIVEXTRO for the treatment of acute bacterial skin and